Market evolution: Bulk medicaments (CN 3003) — 2015–2025

Introduction

This report examines the trade dynamics of EU extra-EU commerce in CN 3003 — bulk medicaments consisting of two or more constituents mixed together for therapeutic or prophylactic uses, not in measured doses or put up for retail sale. The period 2015–2025 was marked by dramatic structural changes: the UK's departure from the EU customs territory, the COVID-19 pandemic, and a broader reshaping of global pharmaceutical supply chains. The data reveal a paradox at the heart of EU trade — export volumes fell by 62% while export unit values doubled, and import volumes rose 47% while import unit values halved. These countervailing movements, combined with a sharp geographic reorientation of trade partners, tell a story of fundamental transformation in how the EU sources and supplies bulk pharmaceutical intermediates.

The analysis is based on the general overview dashboard and associated supplementary views. All figures are drawn directly from the underlying data; no values have been interpolated or estimated.

1. The Great Volume–Price Inversion: Less Volume, More Value — or Is It?

Export volumes collapsed while prices more than doubled

The most striking feature of EU export performance in CN 3003 over the decade is the simultaneous collapse in physical volume and surge in unit value. Total EU exports of bulk medicaments to non-EU countries fell from 40,168 tonnes in 2015 to 15,174 tonnes in 2025 — a 62.2% decline in volume. Over the same period, the average export price rose from €88,180 per tonne to €178,525 per tonne, an increase of 102.5%. In value terms, these opposing trends partially offset each other: total export value declined by 23.5%, from €3.54 billion to €2.71 billion.

This pattern suggests a compositional shift: the EU increasingly exports higher-value, lower-volume medicaments — likely reflecting a move towards more complex active pharmaceutical ingredients (APIs), biologics, or specialty products rather than large-volume generics. The product segment breakdown confirms this: the dominant subheading 300390 (other mixed medicaments) saw its export volume drop from 36,254 tonnes to 12,121 tonnes, while its unit value rose from €91,625 to €194,856 per tonne.

Import volumes grew while unit values fell sharply

The import side tells the mirror image. EU import volumes rose from 13,681 tonnes to 20,158 tonnes (+47.3%), yet import value fell from €3.67 billion to €2.39 billion (−34.8%). The average import price collapsed from €268,144 per tonne to €118,616 per tonne (−55.8%).

This indicates that the EU is importing significantly more bulk medicament volume at much lower unit prices — consistent with a growing reliance on lower-cost generic API suppliers, particularly from India and China, where production costs are structurally lower. The subheading 300390 illustrates this clearly: import volumes in this category surged from 12,003 tonnes to 18,719 tonnes, while the unit value dropped from €278,391 to €103,952 per tonne.

The trade balance flipped from deficit to surplus

The combined effect of these volume-price dynamics was a dramatic improvement in the EU's trade balance for CN 3003. In 2015, the EU ran a trade deficit of €127 million; by 2025, this had turned into a surplus of €318 million — a swing of nearly €450 million (a 349.6% improvement). The deficit reached its worst point at −€1.05 billion in an intermediate year, before recovering. The net import reliance indicator confirms this trajectory: the EU moved from a net import reliance of −12.5% (moderate net exporter) through a period of positive reliance (net importer, peaking at 9.8%) and back to approximately balanced (−0.6%) by 2025.

The COVID-19 pandemic created a pronounced trough in 2021

Both exports and imports reached their minimum values in 2021: exports fell to just €1.21 billion and imports to €1.48 billion. This likely reflects pandemic-related disruptions to pharmaceutical manufacturing, logistics, and demand patterns. The year 2021 also saw an anomalous spike in insulin (300331) imports: volume surged to 1,422 tonnes compared to a normal range of 3–60 tonnes in adjacent years, possibly reflecting emergency stockpiling or supply chain rerouting.

2. Post-Brexit Reorientation: From a UK-Centred Market to a Multipolar One

Exports to the United Kingdom collapsed almost entirely

The single most dramatic geographic shift in EU CN 3003 trade over this period was the near-total collapse of exports to the United Kingdom. In 2015, the UK was by far the EU's largest export destination for bulk medicaments, absorbing €2.46 billion — representing roughly 69% of total extra-EU export value. By 2025, exports to the UK had fallen to just €85 million, a decline of 96.6%.

While the UK data spans the entire period — and the sharpest decline coincides with the end of the Brexit transition period in 2021 — the magnitude of the drop is exceptional. It suggests that pharmaceutical supply chains that previously operated seamlessly within the EU single market were substantially restructured, with UK-bound trade either ceasing, being rerouted, or shifting to domestic UK production.

The United States became the dominant export partner

As UK-bound exports evaporated, the United States surged to become the EU's largest extra-EU export market. US-bound exports grew from €216 million to €1.13 billion (+423.6%), making the US the destination for over 40% of EU CN 3003 exports by 2025. This reflects the deepening integration of EU pharmaceutical manufacturers into the US market — the world's largest — likely driven by contract manufacturing, API supply agreements, and the relocation of supply chains post-Brexit.

Exports to Russia (+438%) and China (+314.8%) also grew rapidly, though from lower bases. The Russia growth may partly reflect pre-2022 expansion before geopolitical disruptions; the data shows Russia at €261 million in 2025, suggesting continued trade despite sanctions discussions (though the specifics depend on the exact timing and product coverage).

Import sources diversified but concentrated among major suppliers

On the import side, the United States consolidated its position as the EU's top supplier of bulk medicaments, with imports rising from €793 million to €1.34 billion (+68.6%). The US now accounts for over half of EU CN 3003 imports by value.

India (+149.3%) and China (+159.6%) more than doubled their export volumes to the EU, consistent with the global trend of generic API production shifting to Asia. Switzerland also grew strongly (+84%), reflecting its role as a major pharmaceutical hub (home to Novartis, Roche, etc.). The UK's role as an import source also declined (−60.9%), mirroring the broader post-Brexit supply chain adjustments.

Trade volatility varied sharply by partner

The volatility analysis reveals that certain trade corridors were far more unstable than others. Imports from Singapore showed the highest volatility (CV of 2.45), followed by South Africa (1.72) and Canada (1.21). On the export side, Australia (CV 1.57) and Korea (1.41) were the most volatile destinations. By contrast, Switzerland, Japan, and India on the import side, and Algeria, Egypt, and Japan on the export side, showed relatively stable trade patterns (CVs below 0.30).

Notable shock events include a price shock in exports to Ukraine centred on 2017 (abnormality score 225.6, shift +446.5%) and a price shock in imports from China in 2021 (abnormality 98.3, shift +87.4%), the latter coinciding with the pandemic period.

3. Domestic Production Surge, Shifting Specialisation, and Rising Import Concentration

EU production of bulk medicaments more than doubled

Despite the decline in export volumes, EU domestic production of CN 3003 grew substantially. According to the production data, production value rose from €4.48 billion to €10.67 billion — an increase of 138.1%. The peak year saw production reach as high as €22.77 billion. This surge reflects massive investment in EU pharmaceutical manufacturing capacity, likely driven by strategic concerns about supply chain resilience (particularly post-COVID), government incentives, and the growing complexity of manufactured products.

The combination of rising production and relatively stable export propensity (declining only slightly from 28.6% to 27.2%, per the export propensity indicator) suggests that much of this production growth served the intra-EU market or replaced imports, rather than driving export expansion.

Ireland and Portugal emerged as the EU's most specialised producers

The specialisation analysis for 2025 identifies Ireland (RSCA: 0.919, RCA: 23.7) and Portugal (RSCA: 0.844, RCA: 11.8) as the EU member states with the strongest revealed comparative advantage in CN 3003.

Ireland's specialisation is long-standing, reflecting its role as a hub for multinational pharmaceutical companies (Pfizer, MSD, etc.), but Portugal's emergence is remarkable. Portuguese exports of bulk medicaments surged from €25 million in 2015 to €537 million in 2025 — an increase of over 2,000%. This elevated Portugal from a marginal player to the EU's largest single exporter of CN 3003, overtaking Germany and the Netherlands.

At the other end of the spectrum, Finland (RSCA: −0.999), Malta (−0.992), Slovakia (−0.979), Slovenia (−0.978), and Latvia (−0.976) show no specialisation whatsoever, with negligible production shares.

Export concentration fell sharply while import concentration rose

A key structural change is visible in the Herfindahl-Hirschman Index (HHI) trends:

The export HHI halved, indicating that EU exports of bulk medicaments are now far more geographically diversified than in 2015. This is the direct consequence of the UK's share collapsing: in 2015, the UK alone absorbed roughly 70% of EU exports, creating extreme concentration. As exports spread across the US, Russia, China, Switzerland, and other markets, the distribution became much more even.

Conversely, import concentration increased by 28.5%. The growing dominance of the United States as a supplier — accounting for over half of import value — combined with Switzerland's strong position, means that EU import sources are becoming more concentrated among fewer, larger partners. This has implications for supply chain vulnerability, should disruptions affect US or Swiss pharmaceutical output.

EU member states experienced divergent trajectories

The intra-EU reallocation of trade flows was equally dramatic. Among importers:

• Belgium saw imports surge from €32 million to €366 million (+1,033%), suggesting the development of a major import hub, possibly linked to Antwerp's logistics infrastructure and pharmaceutical distribution networks.
• Spain grew from €34 million to €169 million (+402%).
• The Netherlands, historically the largest EU importer, saw imports collapse from €1.28 billion to €345 million (−73%), though it remains a top-3 importer.
• Hungary nearly doubled its imports (+99%), reaching €124 million.

Among exporters, the shifts were equally pronounced:

• Portugal's extraordinary rise (from €25 million to €537 million) has already been noted.
• The Netherlands doubled its exports from €131 million to €279 million.
• Ireland grew from €92 million to €206 million.
• Germany and France, the traditional pharmaceutical powerhouses, saw relatively modest changes (+21% and −10% respectively).

Conclusion

The EU's trade in bulk medicaments (CN 3003) underwent a fundamental transformation between 2015 and 2025. Three forces drove this change: Brexit, which shattered the UK-centred export model and forced geographic diversification; the COVID-19 pandemic, which caused a sharp 2021 trough and accelerated supply chain restructuring; and the globalisation of generic API production, which brought Indian and Chinese suppliers deeper into EU import flows while pushing down import unit values.

The net result is an EU pharmaceutical trade landscape that is more geographically diversified on the export side, more concentrated on the import side, and increasingly focused on higher-value products. Domestic production more than doubled, suggesting that a significant share of the "lost" export volume was absorbed by growing intra-EU demand or substituted by domestic output. The trade balance improved from deficit to surplus, but this improvement was driven as much by falling import prices as by export competitiveness.

Looking ahead, the rising concentration of imports among US and Swiss suppliers, combined with the volatility observed in several trade corridors, suggests that supply chain resilience remains a concern. The EU's strategic investment in domestic production capacity — evident in the 138% growth in production value — represents a deliberate effort to mitigate these vulnerabilities, but the data shows that the bloc remains deeply integrated into global pharmaceutical supply networks, with all the opportunities and risks that entails.